Other equities research analysts have also recently issued reports about the stock. Analysts at MLV & Co raised their price target on shares of Affymax from $12.00 to $21.00 in a research note to investors on Monday. They now have a “buy” rating on the stock. Separately, analysts at Auriga reiterated a “buy” rating on shares of Affymax in a research note to investors on Tuesday, May 8th. Finally, analysts at WBB Securities downgraded shares of Affymax from a “strong-buy” rating to a “buy” rating in a research note to investors on Tuesday, May 8th. They now have a $17.00 price target on the stock, up previously from $9.00.
Affymax traded up 2.06% on Monday, hitting $14.39. Affymax has a 1-year low of $3.93 and a 1-year high of $16.25. The company’s market cap is $519.6 million.
Affymax, Inc. is a biopharmaceutical company developing drugs to improve the treatment of serious and often life-threatening conditions.